ArticleBrain, behavior, & immunity - health2026
Presentation and temporal nature of postacute sequelae of SARS-CoV-2 infection in a US national cohort.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postacute Sequelae of SARS-CoV-2 Infection (PASC) is a novel illness emerging from SARS-CoV-2 infection, characterized by the persistence of symptoms beyond resolution of the initial illness. Understanding the phenotypes and trajectory of PASC is critical for diagnosis and development of personalized management approaches for specific PASC syndromes, to ultimately improve quality of life. The aim of this study was to examine the prevalence and duration, and characterize patterns of specific PASC symptoms in a community-based cohort. Method: A non-probabilistic, weighted, cross-sectional survey of 14,964 adults from the US general population from the COVID-19 Outbreak Public Evaluation (COPE) Initiative between March 10, 2022 and June 2, 2022. Results: At 1-month post-infection, 44% of individuals with a history of SARS-CoV-2 infection reported at least one physical symptom, 47% reported at least one mental health symptom and 33% reported at least one cognitive symptom (14%, 10%, and 17% in controls, respectively). The prevalence of specific physical, cognitive and mental health symptoms declined between 1- and 12-months post-infection, to a prevalence rate similar to non-infected controls by 12 months. Cluster analysis revealed the persistence of symptom groups, with loss of taste and smell, psychosocial symptoms, respiratory and cardiovascular symptoms, and brain fog the most prominent at 12 months. Although cognitive symptom clusters persisted to 6 months post-infection, mental health clusters were transient. Conclusions: The prevalence of most common PASC symptoms fell to general population levels within 12 months. Persisting physical and cognitive symptom clusters provide insights into potentially distinct disease pathways, and are essential for guiding clinical management strategies, rehabilitation programs, and public health interventions aimed at mitigating long-term impacts of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.